Dyne Therapeutics (NASDAQ:DYN) Insider Sells $21,915.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Johanna Friedl-Naderer sold 900 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $24.35, for a total transaction of $21,915.00. Following the completion of the sale, the insider owned 153,082 shares in the company, valued at $3,727,546.70. This trade represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Johanna Friedl-Naderer also recently made the following trade(s):

• On Tuesday, September 8th, Johanna Friedl-Naderer sold 185 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.88, for a total transaction of $3,492.80.

Dyne Therapeutics Stock Down 4.0%

Dyne Therapeutics stock opened at $18.42 on Friday. The company has a market cap of $3.44 billion, a P/E ratio of -5.53 and a beta of 1.08. Dyne Therapeutics, Inc. has a 1-year low of $11.92 and a 1-year high of $27.31. The company has a fifty day simple moving average of $24.68 and a 200 day simple moving average of $20.54. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). Research analysts anticipate that Dyne Therapeutics, Inc. will post -3.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DYN. Creative Planning lifted its position in Dyne Therapeutics by 6.8% during the third quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after purchasing an additional 986 shares during the period. Hilton Head Capital Partners LLC bought a new position in Dyne Therapeutics in the 1st quarter valued at about $26,000. Caxton Associates LLP increased its holdings in Dyne Therapeutics by 10.9% in the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after buying an additional 1,627 shares during the period. Steward Partners Investment Advisory LLC raised its position in shares of Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at approximately $51,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Key Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Morgan Stanley reaffirmed its Buy rating on Dyne, signaling continued confidence in the company’s pipeline and long-term outlook. Morgan Stanley reaffirmed Buy rating
• Positive Sentiment: RBC maintained an Outperform rating, saying Dyne’s DM1 approach remains differentiated, although it reduced its price target from $35 to $30. Investors are also awaiting additional six- and 12-month data for DYNE-101 and topline results from the fully enrolled ACHIEVE expansion cohort, expected in the first quarter of 2027. RBC assessment of Dyne’s DM1 approach
• Neutral Sentiment: Unusually heavy call-option activity was reported, with roughly 20,532 calls traded versus average daily volume of about 464. The activity may indicate speculative expectations for a rebound or clinical-data catalyst, but it does not establish improving fundamentals. Unusually large options trading in DYN
• Neutral Sentiment: Reported short interest was zero shares, implying no meaningful short-selling position or days-to-cover exposure based on the figures provided. This is unlikely to be a major near-term trading catalyst.
• Negative Sentiment: JPMorgan downgraded DYN from Neutral to Underweight and cut its price target from $17 to $10. The move followed a rival DM1 therapy’s Phase 3 failure, which raised concerns about clinical and commercial risks across the disease class. JPMorgan downgrade following Novartis setback
• Negative Sentiment: An insider sold 900 shares for approximately $21,915, reportedly to cover tax withholding tied to vested equity awards. The sale was small relative to the insider’s remaining holdings, limiting its fundamental significance, but it may add modestly to cautious sentiment. Dyne insider stock sale

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on DYN. TD Cowen began coverage on Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating on the stock. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday, August 17th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $37.00 price target on shares of Dyne Therapeutics in a research report on Tuesday. JPMorgan Chase & Co. cut Dyne Therapeutics from a “neutral” rating to an “underweight” rating and dropped their price objective for the stock from $17.00 to $10.00 in a research note on Wednesday. Finally, Evercore set a $33.00 price objective on Dyne Therapeutics in a report on Friday, May 15th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $32.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.